LianBio downgraded by BofA Securities with a new price target
$LIAN
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2024 | $5.00 → $3.00 | Buy → Underperform | BofA Securities |
| 12/22/2023 | $7.00 → $4.00 | Buy → Hold | Jefferies |